The Lyfegen Annual Industry Report offers a comprehensive analysis of drug access and pricing agreements across global markets, including the United States, Europe, Latin America, Asia, and Australia.
Leveraging insights from the Lyfegen Agreements Library, which includes 7.000+ public agreements, the report highlights key trends such as the rise of Value-Based Contracts (VBCs), innovative payment models, and the increasing use of outcome-based agreements, installment payments, and subscription models to manage high-cost therapies.
Comprehensive Regional Analyses
Asia
In-depth examination of drug reimbursement frameworks in China, Japan, and South Korea, highlighting the role of regulatory bodies, commercial health insurance, and emerging pricing models.
Europe
Insights into the pricing and reimbursement policies of Germany, Spain, Portugal, and other key markets, focusing on HTA processes, pricing negotiations, and the adoption of innovative agreements like outcome-based models.
United States & Emerging Markets
Overview of Medicaid, Medicare, and private payer trends in the US, alongside a look at expanding value-based agreements in Latin America, Australia, and other global regions.
Trending and Innovative Agreements
Analysis of global rebate management strategies and emerging contracting models, including pay-for-performance, price-volume agreements, and installment-based pricing.
Theme-Specific Research
Focus on high-cost therapies in areas like Alzheimer’s, Dementia, and Cystic Fibrosis, highlighting new reimbursement models that improve access while controlling financial risks.
Examination of gene and cell therapies, the growth of subscription-based pricing models, and evolving approaches to managing budget impact for payers.
Key Industry Trends
The rise of renegotiable drug contracts, allowing for real-world evidence adjustments and price re-evaluations over time.
Growing adoption of outcome-based agreements, installment payments, and hybrid reimbursement models to support sustainable market access for high-cost therapies.
A shift towards data-driven decision-making, leveraging AI-powered insights to optimize pricing, contract negotiations, and payer strategies.
Dear Readers,
As healthcare expenditures continue to rise worldwide, funding that care has become a source of concern for many. We believe that finances should never stop care from being delivered and that Value-Based Contracts are necessary to increasing access.
Despite differences in cost-sharing across global healthcare systems, the role of the Value-Based Contracts has been quite similar. This can be achieved in a number of ways for the same therapy.
Enabling this shift is complex, and technology is critical to automat-ing and accelerating data analysis for drug price negotiations. We are proud of having over 7.000 publicly-available agreements now in our Agreements Library. This insight has been monumental in revealing past trends and agreements and reducing the administrative burden for market access professionals.
Our platform is constantly improving, with the goal of ensuring data is quickly accessible and the process of getting a therapy to market is less manual and laborious, no matter how complex the model is.
Whether a nation’s healthcare system is underfunded or not, we have seen successful implementation of Value-Based Contracts in a range of countries and are hopeful for more progress in 2025.
Sincerely,
Girisha Fernando
CEO & Founder
* By sending this message, you agree to our privacy policy.
Sign up & be the first to know about INNOVATIONS
* By sending this message, you agree to our privacy policy.
